BioSpace News Archive

Increasing prevalence of cancer and increasing use of proton therapy for cancer treatment are some key factors driving market revenue growth.

Major factors driving market revenue growth include increasing use of stem cells to treat various diseases, increasing stem cell-based research activities, and growing funding in stem cell-based research.

New results from the DESTINY-Breast03 phase 3 trial showed that ENHERTU® (trastuzumab deruxtecan) demonstrated higher progression-free survival (PFS) and objective response rate (ORR) in prespecified patient subgroups compared to trastuzumab emtansine (T-DM1) in patients with HER2 positive unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane.

Orthobond announced the appointment of Frank P. Cammisa, MD, as the company’s Chief Medical Officer.

Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine, authorizing the use of a single booster dose for administration to individuals 16 and 17 years of age at least six months after completion of primary vaccination with the Pfizer-BioNTech COVID-19 Vaccine.

Pfizer Inc. and BioNTech SE announced that the U.S. Food and Drug Administration has expanded the Emergency Use Authorization of a booster dose of the Pfizer-BioNTech COVID-19 vaccine to include individuals 16 years of age and older.

As the SARS-CoV-2 virus mutates, new variants emerge that can better evade immunity and spread more widely.

Eucure Biopharma, a wholly owned subsidiary of Biocytogen, announced the first patient dosing for a phase I clinical trial of YH004 (anti-4-1BB monoclonal antibody, mAb) (No. YH004002) in Australia.

Halozyme Therapeutics, Inc. announced that its Board of Directors has approved a new share repurchase program effective immediately, which authorizes the Company to purchase up to $750 million of the Company’s outstanding common stock over the next three years.

Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) announced today that the Hart-Scott-Rodino (HSR) antitrust waiting period had expired and that the parties closed the exclusive worldwide collaboration and license agreement between Syndax and Incyte to develop and commercialize axatilimab, Syndax’s anti-CSF-1R monoclonal antibody.